Related Experiment Video
Updated: Aug 14, 2026
Long-term Continuous EEG Monitoring in Small Rodent Models of Human Disease Using the Epoch Wireless Transmitter System
Published on: July 21, 2015
[Clinical study of pentobarbital treatment for status convulsivus in 14 children]
K Kobayashi1, T Watanabe, M Sato
1Department of Pediatrics, Niigata City General Hospital.
Insights
Pentobarbital (PTB) therapy is effective for refractory status convulsivus, particularly when initiated early in cases of encephalitis or encephalopathy. Prompt PTB treatment improves outcomes in pediatric seizure emergencies.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Critical Care Medicine
Background:
- Status convulsivus is a neurological emergency requiring prompt and effective treatment.
- Refractory status convulsivus often necessitates the use of barbiturates like pentobarbital.
- Understanding factors influencing pentobarbital efficacy is crucial for optimizing patient care.
Purpose of the Study:
- To evaluate the efficacy of pentobarbital therapy for pediatric status convulsivus refractory to initial treatments.
- To identify factors affecting pentobarbital's effectiveness in different pediatric patient groups.
- To compare pentobarbital efficacy in status convulsivus secondary to encephalitis/encephalopathy versus epilepsy.
Main Methods:
- Retrospective review of 14 children (4 months to 11 years) with status convulsivus treated with pentobarbital.
- Classification of patient groups: encephalitis/encephalopathy and epilepsy.
- Definition of therapeutic outcomes: Excellent, Effective, and Ineffective.
Main Results:
- Pentobarbital showed variable efficacy in the encephalitis/encephalopathy group (2 excellent, 2 effective, 3 ineffective).
- In cases of encephalitis/encephalopathy with excellent outcomes, shorter seizure duration before treatment and higher loading doses were observed.
- Pentobarbital demonstrated relatively good efficacy in the epilepsy group (4 effective, 1 ineffective).
Conclusions:
- Early initiation of pentobarbital therapy is recommended for refractory status convulsivus, especially in cases of encephalitis or encephalopathy.
- While no single factor directly predicted efficacy, rapid infusion rates correlated with longer treatment durations.
- Pentobarbital remains a valuable option for refractory pediatric status convulsivus, with outcomes influenced by underlying etiology and treatment timing.
Abstract:
We reviewed factors affecting the efficacy of pentobarbital (PTB) therapy for status convulsivus refractory to diazepam, phenytoin and other. The subjects were fourteen children (six boys and eight girls aged from 4 months to 11 years old) with status convulsivus admitted to Niigata City General Hospital, from April 1986 to August 1992. Nine children had status convulsivus secondary to encephalitis or encephalopathy. The other five had status convulsivus associated with epilepsy. The effectiveness of the PTB therapy was defined as follows: 1) Excellent, seizures ceased without recurrence. 2) Effective, seizures ceased but recurred with a decreased dose of PTB. 3) Ineffective, seizures continued so other drugs were necessary, or the patient died. We divided the patients into two groups, encephalitis and encephalopathy, and epilepsy. We estimated the efficacy of PTB in each group. In the encephalitis and encephalopathy group, the effectiveness of PTB was excellent in 2, effective in 2, and ineffective in 3. In the excellent cases there was a tendency that the duration of status convulsivus before the PTB therapy was shorter and the loading dose of PTB was greater. In the epilepsy group, in four cases PTB was effective, and in one ineffective, thus the effectiveness of PTB was relatively good. There was no factor that directly affected the efficacy of PTB therapy, but patients who required a rapid rate of infusion of PTB needed PTB therapy for a longer time. These findings indicate that PTB therapy should be started as soon as possible in cases of refractory status convulsivus due to encephalitis or encephalopathy.
